

# Detection and characterization of Carbapenem resistant Gram-negative bacilli isolates recovered from hospitalized patients at Soba University Hospital, Sudan

**Hana S. Elbadawi**

University of Khartoum

**Kamal M. Elhag**

University of Khartoum

**Elsheikh Mahgoub**

University of Khartoum

**Hisham N Altayb**

University of Khartoum

**Ayman Ahmed**

University of Khartoum

**Francine Ntoumi**

FCRM

**Linzy Elton**

University College London Institute for Global Health

**Timothy D McHugh**

University College London Institute for Global Health

**Mohamed Osman**

York University

**John Tembo**

University of Zambia

**Francesco Vairo**

Universita degli Studi di Roma La Sapienza Facolta di Medicina e Psicologia

**Giuseppe Ippolito**

Institut mikrobiologii imeni S N Vinogradskogo RAN

**Abdinasir Osman**

Brunel University College of Health and Life Sciences

**Alimuddin Zumla**

University College London Institute for Global Health

**Muzamil Mahdi Abdel Hamid** (✉ [mahdi@iend.org](mailto:mahdi@iend.org))

University of Khartoum <https://orcid.org/0000-0002-6157-4388>

---

## Research article

**Keywords:** Hospitalized patients, Carbapenemase resistant genes, Multidrug-resistant, Gram negative bacteria, Sudan

**Posted Date:** January 19th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-43536/v2>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** Antimicrobial resistance (AMR) poses a complex threat to global health security and universal health coverage. Over recent decades, there has been an increase globally in reports of nosocomial infections caused by carbapenem-resistant Gram-negative bacilli (GNB). We aimed to explore the molecular characterization and detection of genes associated with carbapenem producing Gram negative bacteria isolated from hospitalized patients in Soba University Hospital (SUH) in Khartoum State, Sudan.

**Results:** A total of 206 GNB clinical specimens were collected between October 2016 and February 2017 from hospitalized patients in SUH. Of 206 carbapenem resistance isolates, 171 (83%) were confirmed as phenotypically resistant and 121 (58.7%) isolates harboured one or more carbapenemase genes. New Delhi metallo- $\beta$ -lactamase (NDM) types were the most predominant genes, *bla*NDM 107(52%). Others included *bla*IMP 7 (3.4%), *bla*OXA-48 5(2.4%) and *bla*VIM 2 (0.9%) Co-resistance genes with NDM producing GNB were detected in 87 (81.3%) of all *bla*NDM producing isolates. NDM1 was the most frequent subtype observed in 75 (70 %) *bla*NDM producing isolates.

**Conclusions:** The frequency of carbapenemase producing bacilli was found to be high in SUH. NDM was found to be the most prevalent carbapenemase gene among clinical isolates. Close surveillance across all hospitals in Sudan is required. The relative distribution of carbapenemase genes among GNB in nosocomial infections in Africa needs to be defined.

## Background

Antimicrobial resistance (AMR) poses a complex threat to global health security and universal health coverage. The prevalence and distribution of antimicrobial resistant bacterial infections in the nosocomial settings in Africa is poorly defined [1,2]. Carbapenems have been considered as a robust group of antibiotics to treat extended spectrum  $\beta$ -lactamase (ESBL)- producing bacteria in the past ten years and are widely prescribed for treatment of multidrug-resistant Gram-negative bacilli in systemic infections [3]. Overuse of these drugs can favor the selection and spread of multidrug resistant bacteria as well as Carbapenem resistant Enterobacteriaceae (CRE) [4] CRE, carbapenem-resistant *Pseudomonas aeruginosa*, and carbapenem-resistant *Acinetobacter baumannii* were ranked as 'critical' and 'high' priority pathogens by the World Health Organization (WHO) in 2017 [5].

Carbapenem resistance is associated with the production of carbapenemase, encoded by what is termed carbapenemase encoding genes, and categorized as four classes of  $\beta$ -lactamase, including class A carbapenemases such as *Klebsiella pneumoniae* carbapenemases (*bla*KPC), imipenem- hydrolyzing  $\beta$ -lactamase (*bla*IMI) and *Serratia marcescens* enzyme (*bla*SME). Class B Metallo-beta-lactamases such as New Delhi Metallo-beta-lactamases (*bla*NDM), verona integron metallo-beta-lactamases (*bla*VIM), imipenemase (*bla*IMP), German imipenemase (*bla* GIM-1) and Sao Paulo Metallo-beta-lactamases (*bla*SPM). While class D carbapenemases including oxacillinase-group (*bla*OXA-48, OXA- 181, OXA-204,

OXA-162, OXA-23, OXA-24) and a rare class C  $\beta$ -lactamase, including cephamycin-hydrolyzing  $\beta$ -lactamase (*bla*CMY-10) [6,7]. Resistance to carbapenems can occur by other mechanisms including overproduction of ESBLs or AmpC enzyme in combination with porin mutations, which reduces outer membrane permeability, and activation of multidrug efflux pumps in response to antibiotic exposure [8]. Plasmids encoding carbapenemases may also carry co-resistance genes for resistance to other  $\beta$ -lactam and non  $\beta$ -lactam antibiotics [7]. There is a significant challenge in controlling the spread of carbapenemases. Surveys of the molecular epidemiology of carbapenemases revealed that the dissemination of carbapenemases, including NDM, VIM, IMP, OXA-48 and KPC producers, are rapid and widespread among healthcare facilities [9].

Detection of carbapenemase producing isolates by clinical microbiology laboratories is essential to provide targeted therapy, antimicrobial stewardship and update local antibiotic guidelines for clinicians. Furthermore, screening of resistance mechanisms using of antimicrobial susceptibility test in addition to detection of genes associated by phenotype and molecular analysis provides confirmation of clinically observed treatment failure. Whilst over the past decade, there has been an increase in reports globally of nosocomial infections caused by carbapenem resistant Gram-negative bacilli (GNB), data from Africa have been scanty and antimicrobial stewardship is not optimally practiced. This study aimed to detect and characterize carbapenem resistance GNB isolated from patients treated at Soba University Hospital in Khartoum state, Sudan.

## Results

### Demographic distribution

The demographic characteristics of the inpatients and the frequency of GNB isolates according to age groups are shown in **Figure 1**. Most of the isolates were from pediatric patients less than one year old (42.5%), followed by age group ranged from 13-80 years (38%) and the rest of pediatric patients age group ranged from 1-12 years (19.5%). Males 53.4% (110/206) were predominant among inpatients, with females at 46.6% (96/206). With regard to the distribution of carbapenemase producers by hospital location, the most carbapenemase producing isolates were found in the Neonatal Intensive Care Unit 32(26%), followed by Medicine wards 26(22%), Pediatric wards 22 (18%), Surgery 18(15%), ICU 15(12%) and the Renal Unit 8(7%). Carbapenemase producing isolates were most frequently distributed among the following clinical specimens; blood (36%) followed by wound samples (24%), urine (21%), body fluids (7%), catheter tips (6%) and sputum samples (6%).

### Antimicrobial susceptibility and phenotypic screening

The antibiotic resistance pattern is shown in **Figure 2**. Out of 206 isolates tested, the highest percentage resistance was 98% and 93.5%, for ampicillin and cephalixin, respectively, followed by amoxicillin clavulanic acid (90%), cefotaxime (89.7%), ceftriaxone (88.4%), ceftazidime (84.2%), aztreonam (66%), temocillin (64%), sulfamethoxazole-trimethoprim (78.4%) and nitrofurantoin (75.2%). The resistance rate

was also high in ciprofloxacin (83.1%), gentamicin (85%) and amikacin (70%). The resistance rate for meropenem and imipenem was 63.1% and 61.6%, respectively.

Phenotypic carbapenemase activity was detected in 171 (83%) of the 206 clinical isolates. These isolates were positive for the production of one or more carbapenemase enzymes. Details of the carbapenemase activity among different isolates and phenotypic tests are given in **Table 1**.

### **Prevalence and distribution of carbapenemase genes among Gram negative bacilli**

One or more carbapenemase genes were detected in 121 (58.7%) of the 206 study isolates using PCR. *bla*NDM was the most commonly detected among the isolates, predominantly in *K. pneumoniae*. *bla*NDM was also detected more often in *A. baumannii*, *P. aeruginosa* and *E. coli*. The most prevalent gene was *bla*NDM 107(52%), followed by *bla*IMP 7 (3.4%), *bla*OXA-48 5(2.4%), *bla*VIM 2 (0.9%) and *bla*KPC 0 (0%). ESBLs were detected among these isolates with high prevalence in 183 isolates (88.8%), with the following genes: *bla*CTXM 126(61.6%), *bla*SHV 84(40.7%) and *bla*TEM 78(37.8). The genes were unevenly distributed among the different study isolates and more details are given in **Table 2**. Co-resistance carbapenemase genes were observed in a small number of isolates; *bla*NDM + *bla*OXA-48 were detected in three isolates, while *bla*NDM+ *bla*VIM and *bla*NDM+ *bla*IMP were detected in two different isolates.

Out of 107 *bla*NDM genes detected, 75 (70 %) were *bla*NDM-1. Other subtypes of *bla*NDM were identified by sequencing, including *bla*NDM-5, and *bla*NDM-6. The sequence of the 14 NDM genes was analyzed to confirm the presumed most prevalent (NDM) gene type and all showed 97-100% similarity with *bla*NDM genes from the NCBI database with accession number MF379688 and MG764089. Thereafter, all sequences have been deposited in the GenBank database under the following accession numbers: MK033562, MK033563, MK033564, MK363705, MK363706, MK363707, MK363708, MK363709, MK363710, MK371542, MK371543, MK371544, MK371545, and MK371546.

### **Co-resistance genes carried with NDM producing Gram-negative bacilli**

Several isolates carried more than one type of gene including *bla*NDM. ESBL were often observed together with *bla*NDM in 87 (81.3%) of *bla*NDM producing isolates (107). Most of the isolates carried *bla*NDM with one ESBL gene in 38(43.5%) as the following: *bla*NDM+ *bla*CTXM in (24 isolates, 27.6%), *bla*NDM+ *bla*TEM (8 isolates, 9.1%), and *bla*NDM+ *bla*SHV (6 isolates, 6.8%). Isolates carried *bla*NDM with two ESBL genes in (39.2%) as the following: *bla*NDM+ *bla*CTXM+ *bla*SHV (10 isolates, 11.5%), *bla*NDM+ *bla*CTXM+ *bla*TEM (10 isolates, 11.5%), *bla*NDM+ *bla*SHV+ *bla*TEM (14 isolates, 16.2%). Isolates carried *bla*NDM with three ESBL genes, *bla*NDM+ *bla*CTXM+ *bla*SHV +*bla*TEM in 15 isolates (17.3%). The distribution of co-resistance genes among different Gram-negative bacilli is shown in **Table 3**.

## **Discussion**

Carbapenems have become the drug of choice for the treatment of severe nosocomial infections caused by Gram-negative bacilli. Carbapenem resistant *Enterobacteriaceae* (CRE) is a considerable health problem globally and are associated with increased mortality [3], and thus rapid detection of carbapenem resistance and adequate treatment of such cases is mandatory in health care settings. This study was undertaken to determine the prevalence of different types of carbapenemase producing bacteria among Gram-negative bacilli isolated from various hospitalised patients at Soba University Hospital. The accurate detection of carbapenemase producing microorganisms is challenging for laboratories and requires phenotypic and genotypic analysis. Of 206 isolates, 171 (83%) were positive by phenotypic analysis, including isolates with resistance to carbapenems. The genotypic analysis detected 121 (58.7%) positive isolates. The finding indicates that the carbapenem resistance investigated is not only associated with enzyme encoding resistant genes but probably due to other resistance mechanisms such as overproduction of ESBLs, which were detected among 183 (88.8%) of the sampled isolates, in addition to porin loss or mutation [10,11].

Our results revealed that the prevalence of carbapenemase production among different Gram-negative isolates is increasing (up to 83%). Of note, this finding is higher than the incidence observed in a previous study conducted in Khartoum State in 2017, which showed a prevalence of 56% by phenotypic tests (unpublished data). The high frequency of MBL in Khartoum State might be attributed to the excessive use of meropenem in the treatment of patients associated with ESBL infections. Our results are in agreement with a study in Egypt, which reported that carbapenem resistance was 62.7% among Enterobacterial [12]. High rates of carbapenem resistance in 28.6% of isolates have also been observed in Uganda by Okoche in 2015 [13]. In Tanzania, the prevalence of carbapenemase producing isolates was 35% [14]. In South Africa, it was found to be 68% [15], and in Nigeria, 11.9% [16]. Carbapenem resistance in low and middle-income countries (LMICs) in Africa is likely to increase as a result of unrestricted usage of antibiotics, as the majority of the population consumes antibiotics without a clinical prescription [17].

Carbapenemase genes have been recently recognized, and these genes are associated with mobile genetic elements that allow their rapid circulation among bacterial isolates. For instance, *bla*NDM has the potential for rapid spread, as evidenced in Turkey and other countries across the globe [18]. In this study, carbapenemase genes were detected using PCR in 121 (58.7%) of the sampled isolates. The most prevalent gene among the isolates was *bla*NDM (88.4%), mainly in *K. pneumonia* and other Gram-negative bacilli, including *A. baumannii*, *P. aeruginosa* and *E. coli*. Our results are comparable with those reported in India, South Africa, Saudi Arabia and other Middle Eastern countries [15,19,20,21].

Carbapenemase genes are reported to be more frequent in some regions. For example, *bla*KPC genes are dominant in some countries such as Greece, Israel, and USA, while *bla*NDM genes are prevalent in isolates reported from the Far East, India, and Pakistan [11]. OXA-48 was first reported from Turkey, followed by reports from Central Asia and Europe [22]. In the current study, the genes were unevenly distributed among the different bacterial isolates. The *bla*NDM gene was found in high prevalence (52%) compared to other genes. Our findings, however, differ with several studies (for instance, in the Okoche study, the most common gene was *bla*VIM (10.7%), and *bla*NDM-1 (2.6%) was the lowest gene [13], while

Mushi reported IMP types were the most predominant at 21.6% in their study [14]. Other studies reported that *bla*OXA-48 was the most prevalent gene [23,24]. In contrast to global reports of a high prevalence of *bla*KPC genes [11, 25], we have not detected *bla*KPC among the tested isolates. NDM variants have been described differing by several amino acid changes include, *bla*NDM-2, *bla*NDM-4, *bla*NDM-5, *bla*NDM-6 and *bla*NDM-7 [26]. In this study, 107 *bla*NDM producer isolates had been identified using PCR, the most common subtype 75 (70 %) was *bla*NDM-1. Other subtypes of *bla*NDM were detected by sequencing including *bla*NDM-5, and *bla*NDM-6 among different Gram-negative bacilli, including *K. pneumoniae*, *E. coli*, *A. baumannii*, *P. aeruginosa* and *Enterobacter spp.*

Carbapenemase producers are becoming highly distributed among Enterobacterales, *A. baumannii*, *P. aeruginosa* and other Gram-negative bacilli. The highest prevalence of carbapenemase production in this study was observed in *K. pneumoniae*, followed by *P.aeruginosa*, *A. baumannii* and *E. coli* **Table 1**. Similar studies in which *K. pneumoniae*, *A. baumannii* and *Pseudomonas spp.* as the most common carbapenemase producing isolates were reported [27,28,29]. The prevalence of carbapenemase producing isolates varies across hospital settings. This variation could be attributed to a wide range of factors including differences in collection time of isolates, study designs and target populations. Common carbapenemase encoding genes have been associated with bacteria isolated from blood, urine, wounds and sputum, as reported in many studies in Africa and India [13,14,16, 30]. In this finding, carbapenem producers were more frequently isolated from blood followed by wounds and urine as these results are compatible with a study in South Africa in which blood was the most common specimen type (25%), followed by urine (22%) [15].

Young patient age has long been considered as a risk factor for Carbapenem resistant Enterobacteriaceae (CRE) infection, which agrees with this study's finding that carbapenemase-producing Gram negative bacilli were most frequent in children less than one year of age, located in the neonatal and pediatric wards. High rates of carbapenem resistant infections were observed among elderly patients from Medicine wards (22%) and ICU (12%), which agrees with another study that found CRE to be more frequently isolated in the elderly [31].

Carbapenem resistant Gram-negative bacilli are usually resistant to other routinely used antimicrobial agents [32–34]. The plasmids carrying carbapenemase genes like *bla*NDM-1 are diverse and can harbor a high number of additional resistance genes (e.g., ESBL-alleles) as well as other carbapenemase genes like *bla*OXA-48, *bla*VIM. These plasmids were considered as the source of multidrug resistance in one single bacterium [20,35]. Moreover, mechanisms of resistance to  $\beta$ -lactam antibiotics via the production of ESBL, AmpC and carbapenemase were also noticed among the isolates that produce different combinations of the enzymes. In the present study, co-resistance of *bla*NDM with *bla*OXA-48, *bla*VIM and *bla*IMP were reported in few isolates. In connection to co-resistance with ESBL, *bla*CTXM, *bla*SHV and *bla*TEM were detected in a high prevalence of *bla*NDM positive isolates. Most of the isolates carried *bla*NDM with one or more ESBL genes. This is in agreement with various studies that have reported co-resistance among clinical isolates [36,37]. These multiple resistance genes found in some isolates, as

observed in this study, are indicative of the existence of multidrug resistant pathogens, which are responsible for treatment failure, outbreaks of infections and higher treatment costs [38].

Sudan is a large country that shares its borders with seven other countries. People move freely between these borders with the potential passage of antibiotic resistant strains. The dynamic movements of people will make it challenging to monitor AMR in these countries, especially at the borders. These challenges may also represent an opportunity for wider continental monitoring and collaboration between countries rather than country-specific. Such an approach will aid in universal and intergovernmental initiatives to control and limit the AMR spread.

## Conclusion

The frequency of carbapenemase producing bacilli was found to be high in Soba University Hospital (SUH). *bla*NDM was found to be the most prevalent carbapenemase gene among clinical isolates. Improved antibiotic stewardship and infection control measures and close surveillance across all hospitals in Sudan is required. The relative distribution of carbapenemase genes among Gram-negative bacilli (GNB) in nosocomial infections in Africa needs to be investigated.

## Methods

### Study design and clinical Isolates

A cross-sectional laboratory-based study was conducted at the microbiology department in Soba University Hospital and Unit of Molecular Biology, Institute of Endemic Diseases (IEND), University of Khartoum; involving Gram negative clinical bacterial isolates, suspected as carbapenemase producing based on breakpoints zone diameter of carbapenems (CLSI, 2017) [39]. These were isolated from cultures of various clinical specimens; blood, urine, wound swabs, sputum, tips of catheters and other body fluids, between 1<sup>st</sup> October 2016 and 25<sup>th</sup> February 2017 from inpatients at Soba University Hospital. Quality control strains [*E. coli* (ATCC #25922) and *P. aeruginosa* (ATCC #27853)] were used in antimicrobial susceptibility testing. Standard biochemical tests were used for primary identification [40] and molecular identification using PCR [8] was used for all study isolates with universal primer (16SrRNA). For species-specific isolates identified on biochemical testing, species-specific primers for *Klebsiella pneumoniae*, *Escherichia coli*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* were used for confirmation [41-54]. . All isolates were stored in 20% glycerol at -20 °C until use.

### Subculture, susceptibility testing, phenotypic screening and confirmatory tests for carbapenemase resistance

Selection of antimicrobial panels and interpretation of disk diffusion for each bacteria was completed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [39].

Isolates were subcultured on blood agar (BA) and then subjected to susceptibility testing with the following antimicrobials (Mast Diagnostic, UK): amoxicillin-clavulanate (AMC) (30µg); cefuroxime (CXM) (30µg); cephalexin (CL)(30µg); ceftriaxone (CRO)(30µg); ceftazidime (CAZ) (30µg); cefotaxime (CTX) (30µg); meropenem (MEM)(10µg); imipenem (IPM) (10µg); amikacin (AK)(30 µg); gentamicin (CN)(10 µg); ciprofloxacin (CIP)(5 µg); trimethoprim-sulfamethoxazole (SXT)(25 µg); temocillin (TEM)(30 µg); aztreonam (AZT)(30 µg). The Kirby Bauer (disk diffusion) was performed; each isolate was swabbed onto Muller-Hinton agar and the antibiotic discs were placed on top, incubated at 37° C for 18-24 hours [39, 40].

Bacterial isolates that showed intermediate or resistance to imipenem or meropenem were considered as suspected carbapenemase producers and were screened. Phenotypic confirmatory tests for carbapenemase production were conducted using the boronic acid synergy test for class A β-lactamases, the EDTA synergy test for metallo-β-lactamase and the Modified Hodge Test (MHT) for Enterobacterales to detect KPC and OXA-48 producers in addition to temocillin sensitivity [46].

### **Molecular identification of carbapenemase encoding genes**

PCR was carried out using a thermal cycler and the following primers (Macrogen, Korea), *blaVIM*, *blaIMP*, *blaNDM*, *blaNDM-1*, *blaKPC*, *blaOXA-48*, *blaTEM*, *blaSHV* and *blaCTX-M* genes were used [47-51]. The reaction was carried out in a total reaction volume of 25 µl (5µl master mix, Maxime RT premix kit) [8]. The purity and integrity of each PCR product was evaluated, and the amplified product was confirmed with reference to the standard DNA ladder.

### **DNA sequencing and genes analysis**

The PCR product of *blaNDM* genes and 16SrRNA were purified and Sanger sequencing was performed by Macrogen Company (*Seoul, Korea*).

### **Bioinformatics analysis**

Firstly, DNA sequences were clarified and determined the overall quality of the sequences by reviewing nucleotide chromatogram by using Finch TV software version 1.4.0 (<http://www.geospiza.com/Products/finchtv.shtml>) to ensure the ambiguous sites. Thereafter, nucleotide sequences of the NDM genes identified were searched for sequence similarity using nucleotide BLAST [52] (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Multiple sequence alignment for highly similar sequences, was retrieved from NCBI using the MEGA version 7 software [53].

### **Statistical analysis**

Data were analysed using SPSS software version 20.0. Cross tabulation was used to present the relationships between data of antimicrobial sensitivity, phenotypic tests and resistant gene detection among the study isolates, qualitative data were performed through  $\chi^2$  test and significance was set at  $p \leq 0.05$ .

# Abbreviations

AK: Amikacin; AMC: Amoxicillin clavulanate; Amp C: Class C  $\beta$ -lactamases; AMR: Antimicrobial resistance; ATCC: American Type Culture Collection; AZT: Azteroname; BLAST: Basic local alignment search tool; bp: Base pair; CAZ: Ceftazidime; CIP: Ciprofloxacin; CL: Cephalexin; CLSI: Clinical and Laboratory Standards Institute; CN: Gentamicin; CPR: Carbapenemase producer *Enterobacteriaceae*; CRE: Carbapenem resistance *Enterobacteriaceae*; CRO: Ceftriaxone; CTX: Cefotaxime; CTX-M: CTX for cefotaximase and M for Munich; CXM: Cefuroxime; DNA: Deoxyribonucleic acid; *E. coli*: *Escherichia coli*; EDTA: Ethylene diamine tetraacetic acid; ESBL: Extended-Spectrum  $\beta$ -Lactamase; GNB: Gram-negative bacilli; ICU: Intensive care unit IEND: Institute of Endemic Diseases; IMP: Imipenemase Metallo- $\beta$ -lactamase; IPM: Imipenem; *K. pneumonia*: *Klebsiella pneumonia*; KPC: *Klebsiella pneumoniae* carbapenemase-producer; LMICs: Low and middle income countries; MBL: Metallo- $\beta$ -lactamas; MDR: Multi drug resistance; MEM: Meropenem; MHT: Modified Hodge test; NDM: New Delhi Metallo- $\beta$ -lactamase; OXA: oxacillinases; *P. aeruginosa*: *Pseudomonas aeruginosa*; PCR: Polymerase Chain Reaction; *S. maltophilia*: *Stenotrophomonas maltophilia*; SHV: Sulphydryl Reagent Variable; SPSS: Statistical Package for the Social Sciences; SUH: Soba University Hospital; SXT: Trimethoprim-sulfamethoxazole; TEM: Named after patient Temoniera; TEM: Temocillin; VIM: Verona integron-encoded Metallo- $\beta$ -lactamase; WHO: World Health Organisation; °C: Celsius degree; 16SrRNA: 16 small ribosomal RNA;  $\mu$ g: Microgram

# Declarations

## Ethics approval and consent to participate

This study was approved by the Institutional Research Ethics Committee of the Institute of Endemic Diseases (IEND), University of Khartoum and Soba University Hospital (Ref: 12/2017). Written informed consent was obtained from all participants.

## Consent for publication

Not applicable.

## Availability of data and materials

The data for the present study, including the genotypes, isolation location and resistance status of each bacterial isolate, will be available upon reasonable request.

## Competing interests

The authors declare that they have no competing interests.

## Funding

This research received partial research fund from the Ministry of Higher Education and Scientific Research, Sudan (grant number SUD/MOH/MMAH/08/2016). FN, LE, TDM, MO, JT, FV, GI, AYO, AZ and MMZ are part of PANDORA-ID-NET Consortium (EDCTP Reg/Grant RIA2016E-1609) funded by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme, which is supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation.

The funders had no role in the study design, data collection, analysis, interpretation or writing of the manuscript.

### **Authors' contributions**

HE, KE, AA and MMAH designed the study. HE carried out the microbiological analysis. HE and HA analysed the data. HE and MMAH wrote the first draft. MMAH, KE, EM, HA, FN, LE, TDM, MO, JT, FV, GI and AZ were major contributors in revising the manuscript critically for important intellectual content. MMAH, EM, and KE supervised the work. MMAH, AH and HA secured funding for the practical work. AZ and AYO revised the final draft. All authors read and approved the final manuscript.

### **Acknowledgments**

We would like to thank the medical and technical staff of Medical Microbiology Department in Soba University Hospital, University of Khartoum for their help in data collection.

FN; LE; TDM; AA; MO; FV; GI; AZ; AYO; MMA are members of the Pan African Network for Rapid Research, Response, and Preparedness for Infectious Diseases Epidemics consortium (PANDORA-ID-NET) - supported by the European and Developing Countries Clinical Trials Partnership (EDCTP2) programme (RIA2016E-1609). AZ is in receipt of a National Institutes of Health Research senior investigator award.

### **Authors' details**

<sup>1</sup>Soba University Hospital, University of Khartoum, Khartoum, Sudan

<sup>2</sup>Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan

<sup>3</sup>Ahfad University for Women, Omdurman

<sup>4</sup>Department of Microbiology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan

<sup>5</sup>Department of Biochemistry, College of Sciences, King Abdul-Aziz University, Jeddah, KSA

<sup>6</sup>Université Marien NGouabi, Fondation Congolaise pour la Recherche Médicale (FCRM), Brazzaville, Congo; Institute for Tropical Medicine, University of Tübingen, Germany

<sup>7</sup>Center for Clinical Microbiology, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, United Kingdom

<sup>8</sup>Centre for Immunology and Infection, Dept. of Biology and Hull York Medical School, University of York, Heslington, York, United Kingdom

<sup>9</sup>UNZA-UCLMS and HERPEZ Research and training programs, University teaching Hospital, Lusaka, Zambia

<sup>10</sup>National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense 292, Rome 00149, Italy

<sup>11</sup> The Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire

<sup>12</sup> UCL Hospitals NIHR Biomedical Research Centre London, London, UK.

## References

1. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ DS. Antimicrobial resistance in Africa: a systematic review. *BMC Infect Dis.* 17(1):616.
2. Kumwenda GP, Sugawara Y, Abe R, Akeda Y, Kasambara W, Chizani K, Takeuchi D, Sakamoto N, Tomono K HS. First Identification and genomic characterization of multidrug-resistant carbapenemase-producing Enterobacteriaceae clinical isolates in Malawi, Africa. *J Med Microbiol.* 10.1099/jm.
3. Hall BG, Barlow M. Evolution of the serine  $\beta$ -lactamases: past, present and future. *Drug Resist Updat.* 2007;7:111–23.
4. Harris P, Paterson D and Rogers B, Facing the challenge of multidrug-resistant gramnegative bacilli in Australia. *Clinical focus.* 2015; 202: 243–247.
5. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics.2017. Available at: [http://www.who.int/medicines/publications/WHO-PPL-Short\\_Summary\\_25Feb\\_ET\\_NM\\_WHO.pdf](http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb_ET_NM_WHO.pdf).
6. Nordmann P, Naas T, Poirel L. Global Spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis.* 2011;17(10):1791–8.
7. Queenan AM, Bush K. Carbapenemases: the Versatile B-Lactamases. *Clin Microbiol Rev.* 2007;20(3):440–58.
8. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V. Identification and screening of carbapenemase-producing Enterobacteriaceae. *Clin Microbiol Infect.* 2012;18:432–8.
9. Fournier S, Lepointeur M, Kassis-Chikhani N, Huang M, BrunBuisson C, Jarlier V, AP-HP Outbreaks Control Group. Link between carbapenemase-producing Enterobacteria carriage and crossborder exchanges: eight-year surveillance in a large French multihospitals institution. *J Travel Med.* 2012; 19:320 – 323.

10. Huang TD, Bogaerts P, Berhin C, Hoebeke M, Bauraing C, Glupczynski Y. Increasing proportion of carbapenemase-producing Enterobacteriaceae and emergence of a MCR-1 producer through a multicentric study among hospital-based and private laboratories in Belgium from September to November 2015. *Eurosurveillance*. 2017;1–9.
11. Pitout JDD, Nordmann P. Carbapenemase-Producing *Klebsiella pneumoniae*, a Key Pathogen Set for Global Nosocomial Dominance. *Anti-microb Agents Chemother*. 2015;59(10):5873–84.
12. Amer WH, Khalil HS, Abd ELWahab MAA. characterization of carbapenem resistant Enterobacteriaceae in Risk factors , phenotypic and genotypic characterization of carbapenem resistant Enterobacteriaceae in Tanta University Hospitals , Egypt. *Int J Infect Control*. 2016;12:1–11.
13. Okoche D, Asiimwe BB, Katabazi FA, Kato L. Prevalence and Characterization of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral. *PLOS*. 2015;48:1–11.
14. Mushi MF, Mshana SE, Imirzalioglu C, Bwanga F. Carbapenemase Genes among Multidrug Resistant Gram Negative Clinical Isolates from a Tertiary Hospital in Mwanza , Tanzania. *Biomed Res Int*. 2014;3–8.
15. Perovic O, Micro FSA, Micro M, Britz E, Chb MB, Chetty V. IN PRACTICE Molecular detection of carbapenemase-producing genes in referral Enterobacteriaceae in South Africa : A short report. *SAMJ*. 2016;106(10):975–7.
16. Yusuf I, Arzai AH, Haruna M, Sharif AA, Getso MI. Detection of multi drug resistant bacteria in major hospitals in Kano. *Brazilian J Microbiol*. 2014;45(3):791–8.
17. Mukonzo JK, Namuwenge PM, Okure G, Mwesige B, Namusisi OK, Mukanga D. Over-the-counter suboptimal dispensing of antibiotics in Uganda. *J Multidiscip Healthc*. 2013;6:303-310. Published 2013 Aug 20.
18. Karabay O, Altindis M, Koroglu M, Karatuna O, Aydemir ÖA. The carbapenem - resistant Enterobacteriaceae threat is growing: NDM - 1 epidemic at a training hospital in Turkey. *Ann Clin Microbiol Antimicrob*. 2016;15:1–6.
19. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. *J Assoc Physicians India*. 2010;58:147-149.
20. Kumarasamy K, Toleman M, Walsh T, Al. E. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. *Lancet Infect Dis*. 2010;10:597–602.
21. Sonnevend Á, Ghazawi A, Hashmey R, Jamal W, Rotimi V, Shibl A, et al. Characterization of carbapenem-resistant Enterobacteriaceae with high rate of autochthonous transmission in the arabian peninsula. *PLoS One*. 2015;10:e0131372.
22. Gülmez D, Woodford N, Palepou M-F, Mushtaq S, Metan G, Yakupogullari Y, et al. Carbapenem-resistant *Escherichia coli* and *Klebsiella pneumoniae* isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. *Int J Antimicrob Agents*. 2008;31:523–6.

23. Dahab RA, Ibrahim AM and Altayb HN. Phenotypic and genotypic detection of carbapenemase enzymes producing gram-negative bacilli isolated from patients in Khartoum State [version 1; peer review: awaiting peer review]. *F1000Research* 2017, **6**:1656 (<https://doi.org/10.12688/f1000research.12432.1>)
24. Memish Z, Assiri A, Almasri M, Al. E. Molecular characterization of carbapenemase production among Gram-negative bacteria in Saudi Arabia. *Microb Drug Resist.* 2015;21(3):307–314.
25. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. *J Intern Med.* 2015;277(5):501-512. doi:10.1111/joim.12342
26. Bonnin A, Nordmann P. First Identification of Novel NDM Carbapenemase , NDM- 7 , in *Escherichia coli* in France. 2013;8(4):1–5.
27. Doi Y, Paterson DL. Carbapenemase-Producing Enterobacteriaceae. *Semin Respir Crit Care Med.* 2015;36:74–84.
28. Zowawi HM, Sartor AL, Sidjabat HE, Balkhy HH, Walsh TR, Johani M Al. Molecular Epidemiology of Carbapenem-Resistant *Acinetobacter baumannii* Isolates in the Gulf Cooperation Council States: Dominance of OXA-23-Type Producers. *J Clinical Microbiol.* 2015;53(3):896–903.
29. Karaaslan A, Soysal A, Gelmez GA, Kadayifci EK. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing *Acinetobacter baumannii* in a newborn intensive care unit in Turkey. *J Hosp Infect.* 2016;92:67–72.
30. Bhaskar MM, Anand R, Harish BN. Prevalence of *bla*NDM-1 producing blood isolates of *Escherichia coli*, *Klebsiella* species and *Enterobacter* species in a tertiary care centre in South India. *J Microbiol Res Rev.* 2013;1(6):61–68.
31. Lin MY, Lyles-Banks RD, Lolans K et al. The importance of long-term acute care hospitals in the regional epidemiology of *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae. *Clin Infect Dis.* 2013;57:1246–52.
32. Yusuf I, Arzai AH, Haruna M, Sharif AA, Getso MI. Detection of multi drug resistant bacteria in major hospitals in Kano, North-West, Nigeria. *Braz. J. Microbiol.* [Internet]. 2014 Sep [cited 2020 June 23]; 45( 3 ): 791-798.
33. Levy HG, Gould I, Endimiani A, Al E. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. *J Chemother.* 2013;25(3):129–140.
34. Legese M hailu, Weldearegay gebre M, Asrat D. Extended-spectrum beta-lactamase- and among Ethiopian children. *Infect Drug Resist.* 2017;10:27–34.
35. Nordmann P, Poirel L, Toleman MA, Walsh T. “Does broad-spectrum B-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?” *J Antimicrob Chemother.* 2011;66(4):689–692.
36. Zhang X, Chen D, Xu G, Huang W, Wang X. Molecular epidemiology and drug resistant mechanism in carbapenem-resistant *Klebsiella pneumoniae* isolated from pediatric patients in Shanghai, China.

PLoS One. 2018;20:1–10.

37. Nithya N, Remitha R, Jayasree PR, Faisal M, Manish Kumar PR. Analysis of beta-lactamases, blaNDM-1 phylogeny & plasmid replicons in multidrug-resistant *Klebsiella* spp. from a tertiary care centre in south India. *Indian J Med Res.* 2017 Jul;146(Supplement):S38–45.
38. Cohen S, Leverstein-Van J, Hall M. Dutch Working Party on the Detection of Highly Resistant Microorganisms. Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteriaceae. *Int J Antimicrob Agents.* 2010;36(3):205–210.
39. CLSI. M100 Performance Standards for Antimicrobial. 27th ed. 2017. 106-143 p.
40. Wauters G, Vaneechoutte M. Approaches to the Identification of Aerobic Gram-Negative Bacteria. In: *Manual of Clinical Microbiology.* 11th ed. Washington, DC; 2015. p. 613–34.
41. Srinivasan R, Karaoz U, Volegova M, MacKichan J, Kato-Maeda M, Miller S, et al. Use of 16S rRNA gene for identification of a broad range of clinically relevant bacterial pathogens. *PLoS One.* 2015;10(2):e0117617.
42. Liu Y, Liu C, Zheng W, Zhang X, Yu J, Gao Q, et al. PCR detection of *Klebsiella pneumoniae* in infant formula based on 16S-23S internal transcribed spacer. *Int J Food Microbiol.* 2008;125(3):230–5.
43. Sabat G, Rose P, Hickey WJ, Harkin JM. Selective and sensitive method for PCR amplification of *Escherichia coli* 16S rRNA genes in soil. *Appl Environ Microbiol.* 2000;66(2):844–9.
44. Spilker T, Coenye T, Vandamme P, LiPuma JJ. PCR-based assay for differentiation of *Pseudomonas aeruginosa* from other *Pseudomonas* species recovered from cystic fibrosis patients. *J Clin Microbiol.* 2004;42(5):2074-2079.
45. Higgins PG, Wisplinghoff H, Krut O, Seifert H. A PCR-based method to differentiate between *Acinetobacter baumannii* and *Acinetobacter* genomic species 13TU. *CMI.* 2007;13:1199–1201.
46. Aguirre-Quiñonero A, Martínez-Martínez L. Non-molecular detection of carbapenemases in Enterobacteriaceae clinical isolates. *Journal of Infection and Chemotherapy.* 2017;23(1): 1-11.
47. Hong D, Bae I, Jang I, Jeong S, Kang H, Lee K. Epidemiology and Characteristics of Metallo- $\beta$ -Lactamase-Producing *Pseudomonas aeruginosa*. *Infect Chemother.* 2015;42(2):81–97.
48. Suwantararat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. *Antimicrob Resist Infect Control.* 2016;1–8.
49. Pasteran F, Mendez T, Guerriero L, Rapoport M, Corso A. Sensitive Screening Tests for Suspected Class A Carbapenemase Production in Species of Enterobacteriaceae. *J Clin Microbiol.* 2009;47(6):1631–9.
50. Lartigue M, Poirel L, Decousser J, Nordmann P. Multidrug-resistant *Shigella sonnei* and *Salmonella enterica* serotype Typhimurium isolates producing CTX $\beta$ -lactamases as causes of community-acquired infection in France. *Clin Infect Dis.* 2005;40:1069–1070.
51. Isturiz RE CC. Antibiotic use in developing countries. *Infect Control Hosp Epidemiol.* 2000;21(6):394–7.

52. Atschul S, Madden T, Schaffer A, et al. Gapped BLAST and PSI-BLAST. A new generation of protein database search programmes. *NucleicAcid Res.* 1997;25:3389–3402.
53. Kumar S, Stecher G, Tamura K. *Molecular Evolutionary Genetics Analysis.* Molecular Biology and Evolution; 2016. p. 1870–4.

## Tables

**Table 1.** Frequency of carbapenemase producing among Gram-negative bacilli by phenotypic tests.

Bacterial Isolates	Positive isolates for a particular phenotypic test				Total N (%)
	EDTA N (%)	MHT+BA N (%)	EDTA+BA N (%)	EDTA+AB+MHT N (%)	
<i>E.coli</i> (n=28)	17 (16.4)	2 (8.3)	3 (11.1)	4 (26.6)	26 (15.2)
<i>Klebsiella spp.</i> (n=82)	41 (39)	10 (41.6)	12 (44.4)	8 (53.3)	71 (41.5)
<i>Pseudomonas spp.</i> (n=45)	19 (18)	9 (37.5)*	4 (14.9)	1 (6.6)	33(19.2)
<i>Acin. baumannii</i> (n=36)	19 (18)	3 (12.6)*	6 (22.2)	2 (13.3)	30 (17.6)
<i>Burkholderia cepacia</i> (n=2)	2 (1.9)	0 (0)	0 (0)	0 (0)	2 (1.2)
<i>Enterobacter spp.</i> (2)	2 (1.9)	0 (0)	0 (0)	0 (0)	2 (1.2)
<i>Other GNB</i> (n=11)	5 (4.8)	0 (0)	2 (7.4)	0(0)	7 (4)
Total (n=206)	105(50.9)	24 (11.7)	27 (13.1)	15 (7.2)	171(83)

(Other Gram-negative bacilli include *Citrobacter species*, *Serratia species*, *Proteus spp.*, *Stenotrophomonas maltophilia*, *Vibrio vulnificus* and *Morganella morganii*)

EDTA positive = Metallo- $\beta$ -lactamase.

-MHT positive = KPC + OXA48      - Boronic acid positive = KPC

-MHT + Boronic acid positive = KPC   -MHT positive + boronic acid negative = OXA 48

Note: MHT applied only for *Enterobacterceae*.

\* These isolates just positive by BA and not MHT.

**Table 2.** Distributions of carbapenemase and ESBL genes among GNB isolates.

Bacterial isolate	Carbapenemase genes					ESBL genes		
	NDM	OXA-48	IMP	VIM	KPC	CTXM	SHV	TEM
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
<i>K. pneumoniae</i> (n=82)	58 (54.3)	1 (20)	3 (43)	1 (50)	0 (0)	53 (41.7)	28(33.4)	32 (40)
<i>E.coli</i> (n=28)	9(8.4)	1 (20)	2 (28.5)	0 (0)	0 (0)	14 (11.6)	6 (7.2)	4 (5)
<i>Pseudomonas Spp.</i> (n= 45)	14(13.1)	2 (40)	2 (28.5)	1 (50)	0 (0)	28 (22.3)	18(21.5)	16 (20)
<i>A. baumannii</i> (n=36)	17 (15.8)	1 (20)	0 (0)	0 (0)	0 (0)	20 (15.7)	24(28.6)	18 (22.5)
<i>Burkholderia</i> (n=2)	0	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.6)	2 (2.4)	4 (5)
<i>Enterobacter Spp.</i> (n=2)	2 (1.8)	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.6)	1(1.2)	1 (1.25)
Other GNB (n= 11)	7 (6.5)	0 (0)	0 (0)	0 (0)	0 (0)	7 (5.5)	4 (5.7)	5(6.25)
Total (n=206)	107 (52)	5(2.4)	7 (3.4)	2 (0.9)	0 (0)	126 (61.1)	84 (40.7)	78 (37.8)

(Other Gram-negative bacilli include *Citrobacter* species, *Serratia* species, *Proteus spp.*, *Stenotrophomonas maltophilia*, *Vibrio vulnificus* and *Morganella morganii*)


Table 3. Co resistance genes with *bla*NDM among Gram-negative bacilli.

<i>Bla genes</i>	<i>K. pn</i>	<i>E.coli</i>	<i>P. aer</i>	<i>A. bau</i>	<i>Enter</i>	Total N (%)
<i>NDM+CTXM</i>	15	2	5	2	0	24 (27.6%)
<i>NDM+SHV</i>	2	0	2	2	0	6 (6.8%)
<i>NDM+TEM</i>	4	1	1	1	1	8 (9.1%)
<i>NDM+CTXM+ SHV</i>	7	0	1	1	1	10 (11.5%)
<i>NDM+CTXM+ TEM</i>	6	2	0	2	0	10 (11.5%)
<i>NDM+SHV+ TEM</i>	7	0	1	6	0	14 (16.2%)
<i>NDM+ All</i>	9	1	3	2	2	15 (17.3%)
Total	50	6	13	16	2	87 (100%)

(*K. pn* = *Klebsiella pneumoniae*, *P. aer* = *Pseudomonasa aeruginosa*,


*A. bau* = *Acinetobacter baumannii*, *Enter*= *Enterobacter spp.*)

# Figures



**Figure 1**

Distribution of bacterial species isolates among different age groups. (Other GNB include Burkholderia cepacia, Citrobacter species, Serratia species, Enterobacter species, Stenotrophomonas maltophilia, Vibrio vulnificus and Morganella morganii)



**Figure 2**

Antimicrobial resistance pattern among different Gram-negative bacilli isolated from patients treated in Soba University Hospital, Khartoum State.